改良CryoMaze III术式在二尖瓣手术合并心房颤动中百分之百的应用
该研究描述一种改良CryoMaze III冷冻消融术式,在2013年6月至2021年3月期间对277例需行二尖瓣手术合并心房颤动的患者全部采用该术式,并通过倾向性匹配与无房颤病史的二尖瓣手术患者比较,发现该术式安全有效,不增加30天死亡率和并发症,且术后卒中更少,停用抗心律失常药物后12个月无房颤率为90%。
要点
- 277例二尖瓣手术合并房颤患者中100%接受了改良CryoMaze III术式。
- 倾向性匹配后,CryoMaze III组主动脉阻断时间和体外循环时间分别比对照组延长10.5分钟和13.4分钟。
- 两组30天死亡率、并发症、起搏器使用、肾功能不全和远期生存无显著差异,CryoMaze III组术后卒中更少。
核心结论
- 改良CryoMaze III技术高效、安全且有效。
- 应教育外科界了解消融的远期获益和该新技术的简易性,以提高对I类指南推荐的治疗合并房颤的采纳。
研究设计与样本
- 单中心研究,2013年6月至2021年3月期间对需行二尖瓣手术合并心房颤动的患者采用改良CryoMaze III术式。
- 采用倾向性匹配比较接受二尖瓣手术且无房颤病史的对照组与CryoMaze III治疗组,匹配后每组n=161。
- 自2018年起,左心房盒式消融采用3分钟冷冻消融,左心房总冷冻消融时间为8分钟,右心房为6分钟。
主要发现
- 277例需行二尖瓣手术合并心房颤动的患者中100%接受了改良CryoMaze III术式。
- 倾向性匹配后,改良CryoMaze III组平均主动脉阻断时间和体外循环时间分别比对照组延长10.5分钟和13.4分钟。
- 两组30天死亡率、并发症、起搏器使用、肾功能不全或远期生存无显著差异,但CryoMaze III组术后卒中更少。
- 停用抗心律失常药物后无房颤生存率为77%(平均随访3.0±2.1年)。
- 12个月时,3分钟消融组停用抗心律失常药物后无房颤率为90%。
临床怎么用
- 作者认为改良CryoMaze III技术高效、安全且有效,并建议教育外科界了解消融的远期获益和该技术的简易性,以提高对I类指南推荐的治疗合并房颤的采纳。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Concomitant atrial fibrillation often goes untreated because of surgeon concerns regarding lesion set complexity and pump times. We describe a new cryoablation procedure to address this. METHODS: From June 2013 to March 2021, a modified CryoMaze III procedure was used using 3 left atrial ± 3 right atrial cryo-applications creating the key lesions of the Cox Maze III procedure. Since 2018, 3-minute cryo-lesions were used for the left atrial box lesion for total cryoablation times of 8 minutes for the left atrium ± 6 minutes for the right atrium. By using propensity matching, patients undergoing mitral valve surgery with no atrial fibrillation history were compared with CryoMaze III-treated patients. RESULTS: A total of 100% of the 277 patients with atrial fibrillation requiring mitral valve surgery ± other procedures received the modified CryoMaze III procedure. After propensity score matching (n = 161 each group), the modified CryoMaze III group had mean crossclamp and bypass times 10.5 and 13.4 minutes longer than the control group, respectively. There were no significant differences in 30-day mortality, morbidity, pacemaker use, renal dysfunction, or late survival between groups, but there were less postoperative strokes in the CryoMaze III group. Freedom from atrial fibrillation off antiarrhythmics was 77% (mean follow-up of 3.0 ± 2.1 years). At 12 months, freedom from atrial fibrillation off antiarrhythmics was 90% for the 3-minute ablation group. Late survival was similar to age- and sex-matched Centers for Disease Control and Prevention controls. CONCLUSIONS: The modified CryoMaze III technique is efficient, safe, and effective. Education of the surgical community regarding the late benefits of ablation and the simplicity of this new technique should improve adoption of the Class I Guidelines to treat concomitant atrial fibrillation.
引用
- McCarthy PM, Cox JL, Kruse J, et al. One hundred percent utilization of a modified CryoMaze III procedure for atrial fibrillation with mitral surgery. J Thorac Cardiovasc Surg. 2022. PMID: 36184316. doi:10.1016/j.jtcvs.2022.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。